Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111205

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111205

APAC Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 260 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 3500
Web Access (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Asia-Pacific Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

Increasing prevalence of the disease

High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

F. Hoffmann-La Roche AG

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)

ZEISS International

Amneal Pharmaceuticals LLC

Elekta

Sun Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd.

Eckert & Ziegler

Accord Healthcare

Angiochem

ANI Pharmaceuticals, Inc.

Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)

AstraZeneca

Cantex Pharmaceuticals, Inc.

CELON LABS

Diffusion Pharmaceuticals Inc.

EnGeneIC

ERC.SA.

Genenta science

Jazz Pharmaceuticals, Inc.

Loxo Oncology (A Subsidiary of Eli Lilly)

Novartis AG

VBL THERAPEUTICS

Viatris Inc.

Zydus Pharmaceuticals, Inc.,

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 VENDOR SHARE ANALYSIS 69
  • 2.12 SECONDARY SOURCES 70
  • 2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL 76
  • 4.2 PORTER'S FIVE FORCES MODEL 77

5 EPIDEMIOLOGY 78

6 PIPELINE ANALYSIS 80

7 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO 82

8 MARKET OVERVIEW 84

  • 8.1 DRIVERS 86
    • 8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME 86
    • 8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D) 86
    • 8.1.3 PRESENCE OF A STRONG PIPELINE 87
    • 8.1.4 GROWING GERIATRIC POPULATION 88
  • 8.2 RESTRAINTS 89
    • 8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT 89
    • 8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT 90
  • 8.3 OPPORTUNITIES 90
    • 8.3.1 INCREASING DRUG APPROVALS 90
    • 8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 91
    • 8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT 91
  • 8.4 CHALLENGES 92
    • 8.4.1 LACK OF NEW TREATMENT 92
    • 8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 92
    • 8.4.3 LACK OF EARLY DETECTION 93

9 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE 94

  • 9.1 OVERVIEW 95
  • 9.2 PRIMARY (DE NOVO) 98
  • 9.3 SECONDARY 98

10 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT 100

  • 10.1 OVERVIEW 101
  • 10.2 SURGERY 104
  • 10.3 RADIOTHERAPY 104
    • 10.3.1 BRACHYTHERAPY 105
    • 10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT) 105
    • 10.3.3 CONFORMAL OR INTENSITY-MODULATED RT 105
    • 10.3.4 RADIOSURGERY 106
  • 10.4 MEDICATIONS 106
    • 10.4.1 TEMOZOLOMIDE 107
      • 10.4.1.1 ORAL 107
      • 10.4.1.1 INTRAVENOUS 107
    • 10.4.2 NITROSOUREAS DRUGS 107
      • 10.4.2.1 CARMUSTINE 108
        • 10.4.2.1.1 PARENTERAL 108
        • 10.4.2.1.2 IMPLANTABLE WAFERS 108
      • 10.4.2.2 LOMUSTINE 108
      • 10.4.2.3 NIMUSTINE 109
      • 10.4.2.4 FOTEMUSTINE 109
    • 10.4.3 TARGETED THERAPY 109
      • 10.4.3.1 BEVACIZUMAB 109
      • 10.4.3.2 OTHERS 109
    • 10.4.4 ANTI-EPILEPTICS 109
      • 10.4.4.1 LEVETIRACETAM 110
      • 10.4.4.2 PHENYTOIN 110
      • 10.4.4.3 CARBAMAZEPINE 110
    • 10.4.5 CORTICOSTEROIDS 110
      • 10.4.5.1 METHYLPREDNISOLONE 111
      • 10.4.5.2 PREDNISONE 111
      • 10.4.5.3 OTHERS 111

11 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE 112

  • 11.1 OVERVIEW 113
  • 11.2 ADULT 116
    • 11.2.1 MALE 116
    • 11.2.2 FEMALE 117
  • 11.3 GERIATRIC 117
    • 11.3.1 MALE 118
    • 11.3.2 FEMALE 118
  • 11.4 CHILD 118

12 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE 120

  • 12.1 OVERVIEW 121
  • 12.2 GENERICS 124
  • 12.3 BRANDED 124

13 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 126

  • 13.1 OVERVIEW 127
  • 13.2 PARENTERAL 130
  • 13.3 ORAL 130
    • 13.3.1 CAPSULES 131
    • 13.3.2 TABLETS 131
    • 13.3.3 POWDERS 131
  • 13.4 OTHERS 131

14 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER 133

  • 14.1 OVERVIEW 134
  • 14.2 HOSPITAL 137
  • 14.3 CLINICS 137
  • 14.4 HOME HEALTHCARE 138
  • 14.5 OTHERS 139

15 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 140

  • 15.1 OVERVIEW 141
  • 15.2 HOSPITAL PHARMACY 144
  • 15.3 RETAIL PHARMACY 144
  • 15.4 ONLINE PHARMACY 145
  • 15.5 OTHERS 145

16 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION 147

  • 16.1 ASIA-PACIFIC 148
    • 16.1.1 JAPAN 158
    • 16.1.2 CHINA 163
    • 16.1.3 INDIA 167
    • 16.1.4 AUSTRALIA 171
    • 16.1.5 SOUTH KOREA 175
    • 16.1.6 SINGAPORE 179
    • 16.1.7 THAILAND 183
    • 16.1.8 INDONESIA 187
    • 16.1.9 PHILIPPINES 191
    • 16.1.10 MALAYSIA 195
    • 16.1.11 VIETNAM 199
    • 16.1.12 REST OF ASIA-PACIFIC 203

17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE 204

  • 17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 204

18 SWOT ANALYSIS 205

19 COMPANY PROFILE 206

  • 19.1 F.HOFFMAN-LA ROCHE 206
    • 19.1.1 COMPANY SNAPSHOT 206
    • 19.1.2 REVENUE ANALYSIS 206
    • 19.1.3 COMPANY SHARE ANALYSIS 207
    • 19.1.4 PRODUCT PORTFOLIO 207
    • 19.1.5 RECENT DEVELOPMENT 207
  • 19.2 AMGEN INC. 208
    • 19.2.1 COMPANY SNAPSHOT 208
    • 19.2.2 REVENUE ANALYSIS 208
    • 19.2.3 COMPANY SHARE ANALYSIS 209
    • 19.2.4 PRODUCT PORTFOLIO 209
    • 19.2.5 RECENT DEVELOPMENTS 209
      • 19.2.5.1 PRODUCT APPROVAL 209
  • 19.3 MERCK & CO., INC 210
    • 19.3.1 COMPANY SNAPSHOT 210
    • 19.3.2 REVENUE ANALYSIS 210
    • 19.3.3 COMPANY SHARE ANALYSIS 211
    • 19.3.4 PRODUCT PORTFOLIO 211
    • 19.3.5 RECENT DEVELOPMENTS 211
      • 19.3.5.1 STRATETIC COLLABORATION 211
      • 19.3.5.2 EVENTS 212
  • 19.4 PFIZER INC. 213
    • 19.4.1 COMPANY SNAPSHOT 213
    • 19.4.2 REVENUE ANALYSIS 213
    • 19.4.3 COMPANY SHARE ANALYSIS 214
    • 19.4.4 PRODUCT PORTFOLIO 214
    • 19.4.5 RECENT DEVELOPMENT 214
      • 19.4.5.1 MERGER 214
  • 19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE) 215
    • 19.5.1 COMPANY SNAPSHOT 215
    • 19.5.2 REVENUE ANALYSIS 215
    • 19.5.3 COMPANY SHARE ANALYSIS 216
    • 19.5.4 PRODUCT PORTFOLIO 216
    • 19.5.5 RECENT DEVELOPMENT 216
      • 19.5.5.1 PARTNERSHIP 216
      • 19.5.5.2 ACQUISITION 217
  • 19.6 ZEISS INTERNATIONAL 218
    • 19.6.1 COMPANY SNAPSHOT 218
    • 19.6.2 REVENUE ANALYSIS 218
    • 19.6.3 PRODUCT PORTFOLIO 219
    • 19.6.4 RECENT DEVELOPMENTS 219
      • 19.6.4.1 PRODUCT EXPANSION 219
  • 19.7 AMNEAL PHARMACEUTICALS LLC 220
    • 19.7.1 COMPANY SNAPSHOT 220
    • 19.7.2 REVENUE ANALYSIS 220
    • 19.7.3 PRODUCT PORTFOLIO 221
    • 19.7.4 RECENT DEVELOPMENTS 221
      • 19.7.4.1 EVENT 221
      • 19.7.4.2 LAUNCH 221
      • 19.7.4.3 ACQUISITION 222
  • 19.8 ELEKTA 223
    • 19.8.1 COMPANY SNAPSHOT 223
    • 19.8.2 REVENUE ANALYSIS 223
    • 19.8.3 PRODUCT PORTFOLIO 224
    • 19.8.4 RECENT DEVELOPMENTS 224
      • 19.8.4.1 PARTNERSHIP 224
  • 19.9 SUN PHARMACEUTICAL INDUSTRIES LTD 225
    • 19.9.1 COMPANY SNAPSHOT 225
    • 19.9.2 REVENUE ANALYSIS 225
    • 19.9.3 PRODUCT PORTFOLIO 226
    • 19.9.4 RECENT DEVELOPMENT 226
      • 19.9.4.1 AGREEMENT 226
  • 19.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 227
    • 19.10.1 COMPANY SNAPSHOT 227
    • 19.10.2 REVENUE ANALYSIS 227
    • 19.10.3 PRODUCT PORTFOLIO 228
    • 19.10.4 RECENT DEVELOPMENT 228
  • 19.11 ECKERT & ZIEGLER 229
    • 19.11.1 COMPANY SNAPSHOT 229
    • 19.11.2 REVENUE ANALYSIS 229
    • 19.11.3 PRODUCT PORTFOLIO 230
    • 19.11.4 RECENT DEVELOPMENT 230
  • 19.12 ACCORD HEALTHCARE 231
    • 19.12.1 COMPANY SNAPSHOT 231
    • 19.12.2 PRODUCT PORTFOLIO 231
    • 19.12.3 RECENT DEVELOPMENT 231
  • 19.13 ANGIOCHEM 232
    • 19.13.1 COMPANY SNAPSHOT 232
    • 19.13.2 PRODUCT PORTFOLIO 232
    • 19.13.3 RECENT DEVELOPMENT 232
      • 19.13.3.1 AGREMEENT 232
  • 19.14 ANI PHARMACEUTICALS, INC. 233
    • 19.14.1 COMPANY SNAPSHOT 233
    • 19.14.2 REVENUE ANALYSIS 233
    • 19.14.3 PRODUCT PORTFOLIO 234
    • 19.14.4 RECENT DEVELOPMENTS 234
      • 19.14.4.1 ACQUISITION 234
  • 19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC. 235
    • 19.15.1 COMPANY SNAPSHOT 235
    • 19.15.2 PRODUCT PORTFOLIO 235
    • 19.15.3 RECENT DEVELOPMENT 235
      • 19.15.3.1 ACQUISITION 235
      • 19.15.3.2 PRODUCT APPROVAL 236
  • 19.16 ASTRAZENECA 237
    • 19.16.1 COMPANY SNAPSHOT 237
    • 19.16.2 REVENUE ANALYSIS 237
    • 19.16.3 PRODUCT PORTFOLIO 238
    • 19.16.4 RECENT DEVELOPMENT 238
      • 19.16.4.1 AGREEMENT 238
  • 19.17 CANTEX PHARMACEUTICALS, INC. 239
    • 19.17.1 COMPANY SNAPSHOT 239
    • 19.17.2 PRODUCT PORTFOLIO 239
    • 19.17.3 RECENT DEVELOPMENT 239
  • 19.18 CELON LABS 240
    • 19.18.1 COMPANY SNAPSHOT 240
    • 19.18.2 PRODUCT PORTFOLIO 240
    • 19.18.3 RECENT DEVELOPMENT 240
  • 19.19 DIFFUSION PHARMACEUTICAL 241
    • 19.19.1 COMPANY SNAPSHOT 241
    • 19.19.2 SERVICES PORTFOLIO 241
    • 19.19.3 RECENT DEVELOPMENT 241
  • 19.20 ERC.SA 242
    • 19.20.1 COMPANY SNAPSHOT 242
    • 19.20.2 PRODUCT PORTFOLIO 242
    • 19.20.3 RECENT DEVELOPMENT 242
      • 19.20.3.1 PIPELINE UPDATE 242
  • 19.21 ENGENEIC 243
    • 19.21.1 COMPANY SNAPSHOT 243
    • 19.21.2 PRODUCT PORTFOLIO 243
    • 19.21.3 RECENT DEVELOPMENTS 243
      • 19.21.3.1 AWARDS 244

122 GENENTA SCIENCE 245

    • 19.22.1 COMPANY SNAPSHOT 245
    • 19.22.2 PRODUCT PORTFOLIO 245
    • 19.22.3 ECENDEVELOPMENT 245
      • 19.22.3.1 EVENT 245
  • 19.23 JAZZ PHARMACEUTICALS, INC. 246
    • 19.23.1 COMPANY SNAPSHOT 246
    • 19.23.2 REVENUE ANALYSIS 246
    • 19.23.3 PRODUCT PORTFOLIO 247
    • 19.23.4 RECENT DEVELOPMENT 247
      • 19.23.4.1 ACQUISITION 247
  • 19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY) 248
    • 19.24.1 COMPANY SNAPSHOT 248
    • 19.24.2 PRODUCT PORTFOLIO 248
    • 19.24.3 RECENT DEVELOPMENT 248
  • 19.25 NOVARTIS AG 249
    • 19.25.1 COMPANY SNAPSHOT 249
    • 19.25.2 REVENUE ANALYSIS 249
    • 19.25.3 PRODUCT PORTFOLIO 250
    • 19.25.4 RECENT DEVELOPMENT 250
  • 19.26 VBL THERAPEUTICS 251
    • 19.26.1 COMPANY SNAPSHOT 251
    • 19.26.2 PRODUCT PORTFOLIO 251
    • 19.26.3 RECENT DEVELOPMENT 251
      • 19.26.3.1 EVENT 251
      • 19.26.3.2 AWARD 252
  • 19.27 VIATRIS INC 253
    • 19.27.1 COMPANY SNAPSHOT 253
    • 19.27.2 REVENUE ANALYSIS 253
    • 19.27.3 PRODUCT PORTFOLIO 254
    • 19.27.4 RECENT DEVELOPMENT 254
      • 19.27.4.1 AGREEMENT 254

  • 19.28 ZYDUS PHARMACEUTICALS, INC. 255
    • 19.28.1 COMPANY SNAPSHOT 255
    • 19.28.2 PRODUCT PORTFOLIO 255
    • 19.28.3 RECENT DEVELOPMENTS 255

20 QUESTIONNAIRE 256

21 RELATED REPORTS 260

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET 55
  • TABLE 2 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 72
  • TABLE 3 ASIA PACIFIC PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 4 ASIA PACIFIC SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 5 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 78
  • TABLE 6 ASIA PACIFIC SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 79
  • TABLE 7 ASIA PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 80
  • TABLE 8 ASIA PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 80
  • TABLE 9 ASIA PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 10 ASIA PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 82
  • TABLE 11 ASIA PACIFIC TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 82
  • TABLE 12 ASIA PACIFIC NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 83
  • TABLE 13 ASIA PACIFIC CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 83
  • TABLE 14 ASIA PACIFIC TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 84
  • TABLE 15 ASIA PACIFIC ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 85
  • TABLE 16 ASIA PACIFIC CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 85
  • TABLE 17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 90
  • TABLE 18 ASIA PACIFIC ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 91
  • TABLE 19 ASIA PACIFIC ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 91
  • TABLE 20 ASIA PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 21 ASIA PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 93
  • TABLE 22 ASIA PACIFIC CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 23 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 98
  • TABLE 24 ASIA PACIFIC GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 25 ASIA PACIFIC BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 26 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 104
  • TABLE 27 ASIA PACIFIC PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 105
  • TABLE 28 ASIA PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 29 ASIA PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 106
  • TABLE 30 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 31 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 111
  • TABLE 32 ASIA PACIFIC HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 112
  • TABLE 33 ASIA PACIFIC CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 34 ASIA PACIFIC HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 35 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 114
  • TABLE 36 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 118
  • TABLE 37 ASIA PACIFIC HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 119
  • TABLE 38 ASIA PACIFIC RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 120
  • TABLE 39 ASIA PACIFIC ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 120
  • TABLE 40 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 121
  • TABLE 41 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 128
  • TABLE 42 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 43 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 44 ASIA-PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 129
  • TABLE 45 ASIA-PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 129
  • TABLE 46 ASIA-PACIFIC TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 129
  • TABLE 47 ASIA-PACIFIC NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 129
  • TABLE 48 ASIA-PACIFIC CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 49 ASIA-PACIFIC TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 50 ASIA-PACIFIC ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 51 ASIA-PACIFIC CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 52 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 53 ASIA-PACIFIC ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 54 ASIA-PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 55 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 56 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 131
  • TABLE 57 ASIA-PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 131
  • TABLE 58 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 132
  • TABLE 59 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 132
  • TABLE 60 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 61 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 62 JAPAN RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 63 JAPAN MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 64 JAPAN TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 65 JAPAN NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 66 JAPAN CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 67 JAPAN TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 68 JAPAN ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 69 JAPAN CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 70 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 71 JAPAN ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 72 JAPAN GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 73 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 74 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 136
  • TABLE 75 JAPAN ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 76 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 137
  • TABLE 77 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 137
  • TABLE 78 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 79 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 138
  • TABLE 80 CHINA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 138
  • TABLE 81 CHINA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 138
  • TABLE 82 CHINA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 83 CHINA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 84 CHINA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 85 CHINA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 86 CHINA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 87 CHINA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 88 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 89 CHINA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 90 CHINA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 91 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 92 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 141
  • TABLE 93 CHINA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 141
  • TABLE 94 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 141
  • TABLE 95 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 141
  • TABLE 96 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 97 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 142
  • TABLE 98 INDIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 142
  • TABLE 99 INDIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 142
  • TABLE 100 INDIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 143
  • TABLE 101 INDIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 143
  • TABLE 102 INDIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 143
  • TABLE 103 INDIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 143
  • TABLE 104 INDIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 143
  • TABLE 105 INDIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 144
  • TABLE 106 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 107 INDIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 108 INDIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 109 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 110 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 145
  • TABLE 111 INDIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 145
  • TABLE 112 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 145
  • TABLE 113 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 145
  • TABLE 114 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 115 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 146
  • TABLE 116 AUSTRALIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 146
  • TABLE 117 AUSTRALIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 146
  • TABLE 118 AUSTRALIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 147
  • TABLE 119 AUSTRALIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 147
  • TABLE 120 AUSTRALIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 147
  • TABLE 121 AUSTRALIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 147
  • TABLE 122 AUSTRALIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 147
  • TABLE 123 AUSTRALIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 148
  • TABLE 124 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 125 AUSTRALIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 126 AUSTRALIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 127 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 128 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 149
  • TABLE 129 AUSTRALIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 149
  • TABLE 130 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 149
  • TABLE 131 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 149
  • TABLE 132 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 133 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 150
  • TABLE 134 SOUTH KOREA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 150
  • TABLE 135 SOUTH KOREA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 150
  • TABLE 136 SOUTH KOREA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 151
  • TABLE 137 SOUTH KOREA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 151
  • TABLE 138 SOUTH KOREA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 151
  • TABLE 139 SOUTH KOREA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 151
  • TABLE 140 SOUTH KOREA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 151
  • TABLE 141 SOUTH KOREA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 152
  • TABLE 142 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 143 SOUTH KOREA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 144 SOUTH KOREA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 145 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 146 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 153
  • TABLE 147 SOUTH KOREA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 153
  • TABLE 148 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 153
  • TABLE 149 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 153
  • TABLE 150 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 151 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 154
  • TABLE 152 SINGAPORE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 154
  • TABLE 153 SINGAPORE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 154
  • TABLE 154 SINGAPORE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 155
  • TABLE 155 SINGAPORE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 155
  • TABLE 156 SINGAPORE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 155
  • TABLE 157 SINGAPORE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 155
  • TABLE 158 SINGAPORE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 155
  • TABLE 159 SINGAPORE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 156
  • TABLE 160 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 161 SINGAPORE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 162 SINGAPORE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 163 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 164 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 157
  • TABLE 165 SINGAPORE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 157
  • TABLE 166 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 157
  • TABLE 167 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 157
  • TABLE 168 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 169 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 158
  • TABLE 170 THAILAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 158
  • TABLE 171 THAILAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 158
  • TABLE 172 THAILAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 159
  • TABLE 173 THAILAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 159
  • TABLE 174 THAILAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 159
  • TABLE 175 THAILAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 159
  • TABLE 176 THAILAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 159
  • TABLE 177 THAILAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 160
  • TABLE 178 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 179 THAILAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 180 THAILAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 181 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 182 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 161
  • TABLE 183 THAILAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 161
  • TABLE 184 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 161
  • TABLE 185 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 161
  • TABLE 186 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 187 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 188 INDONESIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 189 INDONESIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 190 INDONESIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 191 INDONESIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 192 INDONESIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 193 INDONESIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 194 INDONESIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 195 INDONESIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 164
  • TABLE 196 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 197 INDONESIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 198 INDONESIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 199 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 200 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 165
  • TABLE 201 INDONESIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 165
  • TABLE 202 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 165
  • TABLE 203 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 165
  • TABLE 204 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 205 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 206 PHILIPPINES RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 207 PHILIPPINES MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 208 PHILIPPINES TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 209 PHILIPPINES NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 210 PHILIPPINES CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 211 PHILIPPINES TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 212 PHILIPPINES ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 213 PHILIPPINES CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 168
  • TABLE 214 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 215 PHILIPPINES ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 216 PHILIPPINES GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 217 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 218 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 169
  • TABLE 219 PHILIPPINES ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 169
  • TABLE 220 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 169
  • TABLE 221 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 169
  • TABLE 222 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 223 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 224 MALAYSIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 225 MALAYSIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 226 MALAYSIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 227 MALAYSIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 228 MALAYSIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 229 MALAYSIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 230 MALAYSIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 231 MALAYSIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 172
  • TABLE 232 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 233 MALAYSIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 234 MALAYSIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 235 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 236 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 237 MALAYSIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 238 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 173
  • TABLE 239 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 173
  • TABLE 240 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 241 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 242 VIETNAM RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 243 VIETNAM MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 244 VIETNAM TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 245 VIETNAM NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 246 VIETNAM CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 247 VIETNAM TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 248 VIETNAM ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 249 VIETNAM CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 176
  • TABLE 250 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 251 VIETNAM ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 252 VIETNAM GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 253 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 254 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 177
  • TABLE 255 VIETNAM ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 177
  • TABLE 256 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 177
  • TABLE 257 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 177
  • TABLE 258 REST OF ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 178

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 33
  • FIGURE 2 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION 36
  • FIGURE 3 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS 37
  • FIGURE 4 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 38
  • FIGURE 5 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 38
  • FIGURE 6 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING 39
  • FIGURE 7 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 40
  • FIGURE 8 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID 41
  • FIGURE 9 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID 42
  • FIGURE 10 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS 43
  • FIGURE 11 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 47
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 48
  • FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 49
  • FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029 49
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET 59
  • FIGURE 16 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021 69
  • FIGURE 17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION) 70
  • FIGURE 18 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029) 70
  • FIGURE 19 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE 71
  • FIGURE 20 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021 75
  • FIGURE 21 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 76
  • FIGURE 22 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029) 76
  • FIGURE 23 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE 77
  • FIGURE 24 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021 87
  • FIGURE 25 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 88
  • FIGURE 26 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029) 88
  • FIGURE 27 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE 89
  • FIGURE 28 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021 95
  • FIGURE 29 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 96
  • FIGURE 30 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029) 96
  • FIGURE 31 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 97
  • FIGURE 32 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021 101
  • FIGURE 33 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 102
  • FIGURE 34 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 102
  • FIGURE 35 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 103
  • FIGURE 36 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021 108
  • FIGURE 37 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION) 109
  • FIGURE 38 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029) 109
  • FIGURE 39 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE 110
  • FIGURE 40 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021 115
  • FIGURE 41 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 116
  • FIGURE 42 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 116
  • FIGURE 43 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 117
  • FIGURE 44 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2022) 123
  • FIGURE 45 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022) 125
  • FIGURE 46 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 125
  • FIGURE 47 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 126
  • FIGURE 48 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029) 126
  • FIGURE 49 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 178
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!